Sharjah, United Arab Emirates

Mohammed I El-Gamal

USPTO Granted Patents = 2 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2022-2023

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by Mohammed I El-Gamal

Introduction

Mohammed I El-Gamal is a prominent inventor based in Sharjah, United Arab Emirates. He has made significant contributions to the field of cancer research through his innovative patents. With a total of two patents to his name, El-Gamal is recognized for his work in developing selective kinase inhibitors that hold promise for therapeutic applications in cancer treatment.

Latest Patents

El-Gamal's latest patents include groundbreaking discoveries in the realm of anticancer agents. The first patent focuses on the discovery of imidazothiazole- and imidazooxazole-based selective HER4 kinase inhibitors as potential anticancer agents. This novel first-in-class approach aims to provide effective therapeutic formulations and methods for treating cancer. The second patent presents conformationally-restricted analogues of sorafenib and regorafenib, which serve as selective kinase inhibitors for cancer treatment. These innovative analogues are designed for therapeutic formulations and methods aimed at combating cancer.

Career Highlights

El-Gamal is affiliated with the University of Sharjah, where he continues to advance his research in cancer treatment. His work is characterized by a commitment to developing novel therapeutic strategies that can significantly impact patient outcomes. His contributions to the field have garnered attention and respect from peers and institutions alike.

Collaborations

(Section skipped due to space constraints.)

Conclusion

Mohammed I El-Gamal's innovative work in developing selective kinase inhibitors represents a significant advancement in cancer treatment. His patents reflect a dedication to improving therapeutic options for patients facing this challenging disease.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…